var data={"title":"Oxcarbazepine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxcarbazepine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6699?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">see &quot;Oxcarbazepine: Drug information&quot;</a> and <a href=\"topic.htm?path=oxcarbazepine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxcarbazepine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204790\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Oxtellar XR;</li>\n      <li>Trileptal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204791\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Trileptal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054581\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054574\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">see &quot;Oxcarbazepine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Immediate release preparations (oral suspension and tablets) are interchangeable on a mg per mg basis; immediate release and extended release preparations are <b>not</b> bioequivalent and not interchangeable on a mg per mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Partial seizures, monotherapy:</b> Oral: Immediate release (Trileptal): Children and Adolescents 4 to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initiation of monotherapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 8 to 10 mg/kg/day in 2 divided doses; increase dose every third day by 5 mg/kg/day to achieve the recommended monotherapy maintenance dose by weight, as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to &lt;25 kg: 600 to 900 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">25 to &lt;35 kg: 900 to 1,200 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">35 to &lt;45 kg: 900 to 1,500 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">45 to &lt;50 kg: 1,200 to 1,500 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">50 to &lt;60 kg: 1,200 to 1,800 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">60 to &lt;70 kg: 1,200 to 2,100 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;70 kg: 1,500 to 2,100 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to monotherapy:</i> Initial: 8 to 10 mg/kg/day in 2 divided doses, with a simultaneous initial reduction of the dose of concomitant antiepileptic drugs (AEDs); withdraw concomitant AEDs completely over 3 to 6 weeks, while increasing oxcarbazepine dose as needed by no more than 10 mg/kg/day at approximately weekly intervals; increase oxcarbazepine dose to achieve the recommended monotherapy maintenance dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Partial seizures, adjunctive therapy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release (Trileptal):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to &lt;4 years: Initial: 8 to 10 mg/kg/day in 2 divided doses (usual maximum initial daily dose: 600 mg/day); patients &lt;20 kg may require a higher initial dose of 16 to 20 mg/kg/day in 2 divided doses; increase dose slowly over 2 to 4 weeks; maximum daily dose: 60 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents 4 to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial: 8 to 10 mg/kg/day in 2 divided doses (usual maximum initial daily dose: 600 mg/day); increase dose slowly over 2 weeks to the target maintenance dose by weight, as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">20 to 29 kg: 900 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">29.1 to 39 kg: 1,200 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;39 kg: 1,800 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Use of these pediatric target maintenance doses in one clinical trial resulted in doses ranging from 6-51 mg/kg/day (median dose: 31 mg/kg/day) in pediatric patients 4 to 16 years of age (Glauser 2000). In children 2 to 4 years of age, 50% of patients were titrated to a final dose of at least 55 mg/kg/day with target dose of 60 mg/kg/day. Due to a higher drug clearance, children 2 to &lt;4 years of age may require up to twice the dose per body weight compared to adults; children 4 to &le;12 years of age may require a 50% higher dose per body weight compared to adults.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release (Oxtellar XR): Children and Adolescents 6 to 17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 8 to 10 mg/kg/day once daily; maximum initial daily dose: 600 mg/day during the first week of therapy; <b>Note</b>: If initiated with concomitant enzyme-inducing antiepileptic drugs (eg, carbamazepine, phenobarbital, phenytoin), consider dosing adjustments. Increase dose at weekly intervals in 8 to 10 mg/kg/day increments (maximum dosage incremental increase: 600 mg) to the target maintenance dose by weight, as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 29 kg: 900 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">29.1 to 39 kg: 1,200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;39 kg: 1,800 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion from immediate release (Trileptal) to extended release (Oxtellar XR):</b> Higher doses of Oxtellar XR may be necessary; on a mg per mg basis dosage forms are not bioequivalent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Partial seizures; adjunctive therapy (epilepsy):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (Trileptal&reg;): Initial: 600 mg daily in 2 divided doses; dose may be increased by as much as 600 mg/day increments at weekly intervals; recommended daily dose: 1200 mg daily in 2 divided doses. Although daily doses &gt;1200 mg daily were somewhat more efficacious, most patients were unable to tolerate 2400 mg daily (due to CNS effects).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release (Oxtellar XR&trade;): Initial: 600 mg once daily; dosage may be increased by 600 mg/day increments at weekly intervals. Recommended daily dose is 1200-2400 mg once daily. Although daily doses &gt;1200 mg daily were somewhat more efficacious, most patients were unable to tolerate 2400 mg daily (due to CNS effects).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion to monotherapy, partial seizures (epilepsy):</b> Patients receiving concomitant antiepileptic drugs (AEDs): Oral: Immediate release (Trileptal&reg;): Initial: 600 mg daily in 2 divided doses while simultaneously reducing the dose of concomitant AEDs. Withdraw concomitant AEDs completely over 3-6 weeks, while increasing the oxcarbazepine dose in increments of 600 mg daily at weekly intervals, reaching the maximum oxcarbazepine dose (2400 mg daily in 2 divided doses) in about 2-4 weeks (lower doses have been effective in patients in whom monotherapy has been initiated).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Partial seizures; monotherapy (epilepsy):</b> Patients not receiving prior AEDs: Oral: Immediate release (Trileptal&reg;): Initial: 600 mg daily in 2 divided doses. Increase dose by 300 mg daily every third day to a dose of 1200 mg daily. Higher dosages (2400 mg daily) have been shown to be effective in patients converted to monotherapy from other AEDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion from immediate release (Trileptal&reg;) to extended release (Oxtellar XR&trade;):</b> Higher doses of Oxtellar XR&trade; may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (CrCl &lt;30 mL/minute): Immediate release (Trileptal&reg;), Extended release (Oxtellar XR&trade;): Therapy should be initiated at lower starting dose [eg, one-half the usual starting dose (adults: 300 mg daily)] and increased slowly to achieve desired clinical response (eg, adults: Increase in 300-450 mg daily increments at weekly intervals).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD (on dialysis): Immediate release formulations should be used instead of extended release formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: Immediate release (Trileptal&reg;), Extended release (Oxtellar XR&trade;): No dosage adjustments are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (Trileptal&reg;): Use caution (not studied).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release (Oxtellar XR&trade;): Not recommended (not studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204762\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trileptal: 300 mg/5 mL (250 mL) [contains alcohol, usp, methyl hydroxybenzoate, propyl hydroxybenzoate, propylene glycol, saccharin sodium; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/5 mL (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trileptal: 150 mg, 300 mg, 600 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 300 mg, 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxtellar XR: 150 mg, 300 mg, 600 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204747\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12617171\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Trileptal: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM246799.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68nh45h+2sg410MW3pb/XP/w==&amp;TOPIC_ID=12664\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM246799.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Oxtellar XR: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM326087.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5Wbk3HL/5hJBeW0lK/6jL/Zg==&amp;TOPIC_ID=12664\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM326087.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054584\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: May be taken without regard to meals </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suspension: Prior to using for the first time, firmly insert the manufacturer supplied plastic adapter into the neck of the bottle; cover the adapter with child-resistant cap when not in use; shake suspension well (for at least 10 seconds) before use; use manufacturer supplied oral syringe to withdraw appropriate dose; dose may be administered directly from syringe or mixed in a small amount of water immediately prior to use; after use, rinse oral syringe with warm water and allow to dry thoroughly; discard any unused portion 7 weeks after first opening bottle</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: Administer on an empty stomach at least 1 hour before or 2 hours after food. Swallow whole; do not cut, crush, or chew the tablets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133438\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204784\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store tablets and suspension at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store suspension in the original container; use within 7 weeks of first opening container. Dispense extended release tablets in a tight, light-resistant container; protect from light and moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054583\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release; suspension, tablet (Trileptal&reg;): Treatment of partial seizures (FDA approved as monotherapy in ages &ge;4 years and adults; FDA approved as adjunctive therapy in ages &ge;2 years and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release; tablet (Oxtellar XR&trade;): Adjunctive therapy for treatment of partial seizures (FDA approved in ages &ge;6 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6224110\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">OXcarbazepine may be confused with carBAMazepine, oxaprozin, oxazepam</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Trileptal may be confused with TriLipix</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Oxcarbazepine is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204830\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac failure, flushing, hypertension, hypotension, lower extremity edema, orthostatic hypotension, palpitations, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, abnormal electroencephalogram, abnormality in thinking, aggressive behavior, agitation, amnesia, anxiety, apathy, aphasia, ataxia, aura, cerebral hemorrhage, confusion, delirium, delusion, depression, dizziness, drowsiness, dysmetria, dystonia, emotional lability, equilibrium disturbance, euphoria extrapyramidal reaction, falling, fatigue, feeling abnormal, headache, hemiplegia, hyperkinesia, hyperreflexia, hypertonia, hypokinesia, hyporeflexia, hypotonia, hysteria, impaired consciousness, insomnia, intoxicated feeling, lack of concentration, malaise, manic behavior, migraine, myasthenia, nervousness, neuralgia, nightmares, oculogyric crisis, panic disorder, paralysis, personality disorder, precordial pain, psychosis, rigors, seizure, seizure (aggravated), speech disorder, stupor, vertigo, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, contact dermatitis, diaphoresis, eczema, erythematosus rash, facial rash, folliculitis, genital pruritus, maculopapular rash, miliaria, psoriasis, skin photosensitivity, skin rash, urticaria, vitiligo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Change in libido, decreased serum sodium (&lt;135 mEq/L), decreased T4, hot flash, hyperglycemia, hypermenorrhea, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, increased gamma-glutamyl transferase, intermenstrual bleeding, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, aphthous stomatitis, biliary colic, bloody stools, cholelithiasis, colitis, constipation, diarrhea, duodenal ulcer, dysgeusia, dyspepsia, dysphagia, enteritis, eructation, esophagitis, flatulence, gastric ulcer, gastritis, gingival hemorrhage, gingival hyperplasia, hematemesis, hemorrhoids, hiccups, increased appetite, nausea, retching, sialadenitis, stomatitis, upper abdominal pain, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria, hematuria, leukorrhea, priapism, urinary frequency, urinary tract pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bruise, purpura, rectal hemorrhage, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, muscle spasm, right hypochondrium pain, sprain, systemic lupus erythematosus, tetany, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Accommodation disturbance, blepharoptosis, blurred vision, cataract, conjunctival hemorrhage, diplopia, hemianopia, mydriasis, nystagmus, ocular edema, photophobia, scotoma, visual disturbance, xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis externa, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Nephrolithiasis, polyuria, renal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, dyspnea, epistaxis, laryngismus, nasopharyngitis, pleurisy, pneumonia, pulmonary infection, rhinitis, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute generalized exanthematous pustulosis, agranulocytosis, anaphylaxis, aplastic anemia, atrioventricular block, bone fracture (long-term therapy), decreased bone mineral density (long-term therapy), DRESS syndrome, dysarthria, erythema multiforme, falling, folate deficiency, hepatic failure, hepatitis (Hsu 2010), hypoesthesia, hypothyroidism, increased serum amylase, increased serum lipase, leukopenia, multiorgan hypersensitivity (eosinophilia, arthralgia, rash, fever, lymphadenopathy), osteopenia (long-term therapy), osteoporosis (long-term therapy), pancreatitis, pancytopenia, SIADH, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204769\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to oxcarbazepine, eslicarbazepine acetate, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for carbamazepine and analogues is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204751\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Agranulocytosis, leukopenia, and pancytopenia have been reported with use (rare); discontinuation and conversion to alternate therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone disorders: Long term use has been associated with decreased bone mineral density, osteopenia, osteoporosis, and fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Use has been associated with CNS-related adverse events, most significant of these were cognitive symptoms including psychomotor slowing, difficulty with concentration, and speech or language problems, somnolence or fatigue, and coordination abnormalities, including ataxia and gait disturbances. Caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Potentially serious, sometimes fatal, dermatologic reactions (eg, Stevens-Johnson, toxic epidermal necrolysis) have been reported in adults and children; the median time to onset was 19 days after treatment initiation. Monitor for signs and symptoms of skin reactions; discontinuation and conversion to alternate therapy may be required. Recurrence of serious skin reactions have been reported with oxcarbazepine rechallenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic dysfunction: Hepatitis has been reported rarely (Hsu 2010). Promptly evaluate any symptoms of hepatic dysfunction (eg, anorexia, nausea/vomiting, right upper quadrant pain, pruritus) and discontinue therapy immediately if significant abnormalities are confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Rare cases of anaphylaxis and angioedema have been reported, even after initial dosing; permanently discontinue should symptoms occur. Use caution in patients with previous hypersensitivity to carbamazepine (cross-sensitivity occurs in 25% to 30% of patients). Potentially serious, sometimes fatal drug reaction with eosinophilia and systemic symptoms (DRESS) also known as multiorgan hypersensitivity reactions have also been reported in close association with initiation of oxcarbazepine; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, cardiovascular, and/or hematologic organ systems; discontinuation and conversion to alternate therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyponatremia: Clinically significant hyponatremia (serum sodium &lt;125 mmol/L) and syndrome of inappropriate antidiuretic hormone secretion (SIADH) may develop during use; consider monitoring serum sodium (particularly during the first 3 months of therapy) especially in patients at risk for hyponatremia (eg, elderly patients).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Hypothyroidism has been reported; consider monitoring thyroid function, particularly in pediatric patients. Discontinuation of therapy has been associated with return of normal thyroxine levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; patients should be instructed to notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Clinical trials excluded patients with significant cardiovascular disease or ECG abnormalities. Monitor body weight/fluid retention in patients with HF; evaluate serum sodium with worsening cardiac function or fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Single-dose studies show that half-life of the primary active metabolite is prolonged 3- to 4-fold and AUC is doubled in patients with CrCl &lt;30 mL/minute; dose adjustment required in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Exacerbation of or new onset primary generalized seizures has been reported, particularly in children. In case of seizure aggravation, discontinue oxcarbazepine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asian ancestry: Consider screening patients of Asian descent for the variant human leukocyte antigen (HLA) allele B*1502 prior to initiating therapy. This genetic variant has been associated with a significantly increased risk of developing Stevens-Johnson syndrome and/or toxic epidermal necrolysis in patients receiving carbamazepine. Structural similarity of oxcarbazepine to carbamazepine, available clinical evidence, and data from nonclinical studies showing a direct interaction of oxcarbazepine with the HLA-B*1502 protein suggest patients receiving oxcarbazepine may also be at a similar risk. Consider avoiding use of oxcarbazepine in patients with a positive result. Screening is not recommending in low-risk populations or in current oxcarbazepine patients (risk usually during first few months of therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26020438\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Usual onset of hyponatremia (ie, serum sodium &lt;125 mEq/L) is within first 3 months of therapy with immediate release formulation, but has been reported in patients &gt;1 year after initiation; reported incidence: Immediate release: 2.5%; extended release: 1.2%. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">CNS adverse effects may occur, including somnolence (children: ~35%), fatigue, coordination abnormalities [ataxia and gait disturbances (children: 23%)], and cognitive symptoms [eg, difficulty concentrating, speech or language problems, and psychomotor slowing (5.8%)]; these effects may be more common when oxcarbazepine is used as add-on therapy versus monotherapy. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Trileptal and Oxtellar XR are not bioequivalent and not interchangeable on a mg-per-mg basis; systemic absorption and resulting serum concentrations are lower with once daily Oxtellar XR compared to twice daily Trileptal when administered at the same total daily dose; higher doses of Oxtellar XR may be necessary. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204818\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Induces</b> CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204756\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12664&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of OXcarbazepine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: OXcarbazepine may decrease the serum concentration of Bictegravir.  Management: When possible consider using an alternative anticonvulsant with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: OXcarbazepine may decrease the serum concentration of Cobicistat.  Management: Consider an alternative antiepileptic when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of OXcarbazepine. Specifically, the concentrations of the 10-monohydroxy active metabolite of oxcarbazepine may be decreased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: OXcarbazepine may decrease the serum concentration of Dolutegravir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: OXcarbazepine may decrease the serum concentration of Elvitegravir.  Management: For elvitegravir plus a ritonavir-boosted protease inhibitor, use of oxcarbazepine is not recommended; for elvitegravir/cobicistat/emtricitabine/tenofovir combination products, consider using an alternative antiepileptic when possible.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eslicarbazepine: May enhance the adverse/toxic effect of OXcarbazepine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): OXcarbazepine may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: OXcarbazepine may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LevETIRAcetam: OXcarbazepine may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May increase the serum concentration of OXcarbazepine. OXcarbazepine may decrease the serum concentration of Perampanel. Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with oxcarbazepine.  Patients receiving this combination should be followed closely for response, especially with any changes to oxcarbazepine therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of PHENobarbital. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): OXcarbazepine may decrease the serum concentration of Progestins (Contraceptive).  Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: OXcarbazepine may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selegiline: OXcarbazepine may enhance the serotonergic effect of Selegiline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: OXcarbazepine may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sofosbuvir: OXcarbazepine may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Alafenamide: OXcarbazepine may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: OXcarbazepine may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May decrease the serum concentration of OXcarbazepine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204758\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204772\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Oxcarbazepine, the active metabolite MHD and the inactive metabolite DHD, crosses the placenta and can be detected in the newborn (Myllynen 2001). According to the manufacturer, data from a limited number of pregnancies collected from pregnancy registries suggest congenital malformations associated with oxcarbazepine monotherapy, including craniofacial defects and cardiac malformations. In general, the risk of teratogenic effects is higher with AED polytherapy than monotherapy (Harden 2009). Plasma concentrations of MHD gradually decrease due to physiologic changes which occur during pregnancy; patients should be monitored during pregnancy and postpartum. Oxcarbazepine may decrease plasma concentrations of hormonal contraceptives.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Data collection to monitor pregnancy and infant outcomes following exposure to oxcarbazepine is ongoing. Patients exposed to oxcarbazepine during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054580\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Seizure frequency, duration and severity; symptoms of CNS depression (dizziness, headache, somnolence); consider monitoring serum sodium (particularly during first three months of therapy) especially in patients who receive other drugs that may cause hyponatremia and in patients with symptoms of hyponatremia; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes); hypersensitivity reactions; periodic thyroid function tests (particularly pediatric patients); CBC </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27259151\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">The metabolite of oxcarbazepine, 10-monohydroxy metabolite (MHD), is considered the active entity primarily responsible for the therapeutic effects. A clear correlation between MHD plasma concentrations and therapeutic response has not been demonstrated. A number of studies which included pediatric patients down to 1 year of age have suggested optimal MHD concentrations for efficacy may range from 2 to 55 mcg/mL and some experts suggest a target range of 8 to 35 mcg/mL based on clinical experience; however, a high degree of variability has been observed and within the pediatric population, the influence of pharmacokinetic differences in younger pediatric patients (faster MHD clearance) on therapeutic range have not been defined. Therapeutic drug monitoring of MHD is not routinely warranted; however, it may be beneficial in optimizing seizure control in the following situations: Extremes of age, pregnancy, to investigate the correlation between drug concentrations and toxicity especially with concurrent disease states such as renal impairment, to identify potential drug interactions, to assess reasons for therapeutic failure, or to rule out noncompliance (Bring 2008; May 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204750\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pharmacological activity results from both oxcarbazepine and its monohydroxy metabolite (MHD). Precise mechanism of anticonvulsant effect has not been defined. Oxcarbazepine and MHD block voltage-sensitive sodium channels, stabilizing hyperexcited neuronal membranes, inhibiting repetitive firing, and decreasing the propagation of synaptic impulses. These actions are believed to prevent the spread of seizures. Oxcarbazepine and MHD also increase potassium conductance and modulate the activity of high-voltage activated calcium channels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204768\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: MHD: V<sub>d</sub>: 49 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Oxcarbazepine: 67%; MHD: 40%, primarily to albumin; parent drug and metabolite do not bind to alpha-1 acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Oxcarbazepine is extensively metabolized in the liver to its active 10-monohydroxy metabolite (MHD); MHD undergoes further metabolism via glucuronide conjugation; 4% of dose is oxidized to the 10,11-dihydroxy metabolite (DHD) (inactive); 70% of serum concentration appears as MHD, 2% as unchanged oxcarbazepine, and the rest as minor metabolites; <b>Note:</b> Unlike carbamazepine, autoinduction of metabolism has not been observed and biotransformation of oxcarbazepine does not result in an epoxide metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Immediate release tablets and suspension have similar bioavailability (based on MDH serum concentrations). Extended release tablets and immediate release products are not bioequivalent. Immediate release: Decreased in children &lt;8 years; increased in elderly &gt;60 years </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (Rey 2004): 2 to 5 years: MHD: Single dose: Mean range: 4.8 to 6.7 hours; 6 to 12 years: MHD: Single dose: Mean range: 7.2 to 9.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate release: Parent drug: 2 hours; MHD: 9 hours; renal impairment (CrCl 30 mL/minute): MHD: 19 hours; Extended release: Parent drug: 7 to 11 hours; MHD: 9 to 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to 12 years: Immediate release: Oxcarbazepine: 1 hour; MHD: 3 to 4 hours (Rey 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate release: MHD: Tablets: Median: 4.5 hours (range: 3 to 13 hours); Suspension: Median 6 hours; Extended release: MHD: 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (95%, &lt;1% as unchanged oxcarbazepine, 27% as unchanged MHD, 49% as MHD glucuronides, 3% as DHD (inactive), and 13% as conjugate of oxcarbazepine and MHD); feces (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance (per body weight): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to &lt;4 years: Increased by &sim;80% compared to adults </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 to 12 years: Increased by &sim;40% compared to adults</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;13 years: Values approach adult clearance  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204771\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (OXcarbazepine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (250 mL): $273.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Trileptal Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (250 mL): $455.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Oxtellar XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $735.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $1,022.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $1,871.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (OXcarbazepine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $144.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $263.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $485.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Trileptal Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (1): $5.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (1): $9.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (1): $17.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204775\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actinium (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Barzepin (ID);</li>\n      <li>Carbox (BD, LK, PH);</li>\n      <li>Deprectal (MX);</li>\n      <li>Leptal (BD);</li>\n      <li>Lonazet (CO);</li>\n      <li>Neurtrol (TW);</li>\n      <li>Ocnobel (JP);</li>\n      <li>Oksapin (UA);</li>\n      <li>Oleptal (PH);</li>\n      <li>Oxalepsy (PK);</li>\n      <li>Oxalept (HR);</li>\n      <li>Oxazep (BD);</li>\n      <li>Oxcar (PY);</li>\n      <li>Oxetol (BD, LK, MX);</li>\n      <li>Oxpin (KR);</li>\n      <li>Oxrate (IN);</li>\n      <li>Oxypine (TW);</li>\n      <li>Pharozepine (ID);</li>\n      <li>Prolepsi (ID);</li>\n      <li>Sytoclon (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Timox (DE);</li>\n      <li>Trexapin (IL);</li>\n      <li>Trileptal (AE, AR, AT, AU, BB, BE, BG, BH, BO, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GB, GR, HK, HR, ID, IE, IQ, IR, IS, IT, JO, KW, LB, LK, LT, LV, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PH, PL, PR, PY, QA, RO, RU, SA, SE, SI, SK, SY, TH, TR, TW, UY, VE, YE);</li>\n      <li>Trileptin (IL);</li>\n      <li>Tryleptal (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bring P, Ensom MH. Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. <i>Clin Pharmacokinet</i>. 2008;47(12):767-778.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/abstract-text/19026033 /pubmed\" target=\"_blank\" id=\"19026033 \">19026033 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, Nigro M, Sachdeo R, et al, &ldquo;Adjunctive Therapy With Oxcarbazepine in Children With Partial Seizures. The Oxcarbazepine Pediatric Study Group,&rdquo; <i>Neurology</i>, 2000, 54(12):2237-44. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/abstract-text/10881246/pubmed\" target=\"_blank\" id=\"10881246\">10881246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsu HF, Huang SY. Severe hepatitis associated with administration of oxcarbazepine. <i>Pediatr Int.</i> 2010;52(4):677-678. doi: 10.1111/j.1442-200X.2010.03154.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/abstract-text/20958883/pubmed\" target=\"_blank\" id=\"20958883\">20958883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. <i>Clin Pharmacokinet</i>. 2003;42(12):1023-1042.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/abstract-text/12959634 /pubmed\" target=\"_blank\" id=\"12959634 \">12959634 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rey E, Bulteau C, Motte J, et al, &quot;Oxcarbazepine Pharmacokinetics and Tolerability in Children With Inadequately Controlled Epilepsy,&quot; <i>J Clin Pharmacol</i>, 2004, 44(11):1290-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/abstract-text/15496647/pubmed\" target=\"_blank\" id=\"15496647\">15496647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tecoma ES, &ldquo;Oxcarbazepine,&rdquo; <i>Epilepsia</i>, 1999, 40(Suppl 5): S37-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/abstract-text/10530693 /pubmed\" target=\"_blank\" id=\"10530693 \">10530693 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trileptal (oxcarbazepine) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12664 Version 211.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204790\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F204791\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054581\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054574\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204762\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F204747\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F12617171\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054584\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133438\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F204784\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054583\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6224110\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204830\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204769\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204751\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26020438\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F204818\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204756\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F204758\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204772\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054580\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F27259151\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204750\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F204768\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F204771\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F204775\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12664|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">Oxcarbazepine: Drug information</a></li><li><a href=\"topic.htm?path=oxcarbazepine-patient-drug-information\" class=\"drug drug_patient\">Oxcarbazepine: Patient drug information</a></li></ul></div></div>","javascript":null}